TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01689623
Drug: TMC435
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type=exact number, unit=mg, number=150, form=capsule, route=oral. TMC435 will be administered at a dose of 150 mg once daily from Day 4 until Day 15.
Study: NCT01689623
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Type=exact number, unit=mg, number=40, form=tablet, route=oral. Simvastatin will be administered as a single oral 40-mg on Day 1 and Day 13.
Study: NCT00369226
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Infusion for a total of 4 doses
Study: NCT00525733
Drug: FTC 200 mg/TDF 300mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emtricitabine/tenofovir DF fixed-dose tablet containing 200 mg of emtricitabine and 300 mg of tenofovir DF will be administered orally as one tablet once daily (may be taken with or without food)
Study: NCT03659149
Drug: CKD-333 formulation I
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet administered before the breakfast(single-dose)
Study: NCT03659149
Drug: CKD-333 formulation II
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet administered before the breakfast(single-dose)
Study: NCT02238314
Drug: Nucleoside Reverse Transcriptase Inhibitor (NRTI)
Normalized name: Non-nucleoside reverse transcriptase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02238314
Drug: Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)
Normalized name: Non-nucleoside reverse transcriptase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02947165
Drug: PDR001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1 antibody tested on a Q3W regimen or alternative Q4W regimen.
Study: NCT02638207
Drug: NewGam
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the Dose-evaluation Phase, all patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (0.5, 1.0 or 2.0 g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days). If a patient is randomized to receive the low or medium NewGam dose, the same volume with the same infusion rate as would have been applied in case the patient would have been randomized to 2.0 g/kg NewGam will be used, thus supplemented with an authorized 0.9% w/v isotonic sodium chloride solution as appropriate and detailed in the following infusion bag split to maintain the blinding
Study: NCT02472223
Drug: Betadine 5%
Normalized name: Betadine 5% Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: One time in-office administration (4-5 drops) of Betadine 5% limited to 2 minutes, followed by saline lavage.~Betadine 5% exposure to the ocular surface is limited to 2 minutes in-office administration, followed by saline lavage per labeling instructions.
Study: NCT02969681
Drug: ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.5g/kg/day, D1-3, every 2 weeks
Study: NCT02969681
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: * mFOLFOX6~* Oxaliplatin 85 mg/m² d1 concurrent with~* Leucovorin 400 mg/m², followed by~* Bolus 5FU 400 mg/m² , followed by~* Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks~with or without bevacizumab 5mg/kg, every 2 weeks
Study: NCT01735669
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00150228
Drug: CP-526,555 (varenicline)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02165293
Drug: RO7033877 + Bronchoscopy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days 1, 2, and 3: 2.5 mg/kg RO7033877 infused IV over 2 hours, every 8 hours for a total of 7 doses; BAL procedure on Day 3.
Study: NCT02435680
Drug: MCS110
Approvals — FDA: no, EMA: no, PMDA: no
Description: taken by I.V
Study: NCT02521233
Drug: Candesartan + Chlorthalidone (8mg+12,5mg)
Normalized name: candesartan cilexetil 8 MG
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02521233
Drug: Candesartan + Chlorthalidone (8 mg + 25 mg)
Normalized name: chlorthalidone 25 MG
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02521233
Drug: losartan+hydrochlorothiazide
Normalized name: hydrochlorothiazide / losartan
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01777542
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive twice daily subcutaneous injections of a saline solution (placebo).
Study: NCT01386242
Drug: Recombinant anti-tumor and anti-virus protein for injection
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant anti-tumor and anti-virus protein for injection,10μg,im,twice per week for first 2 weeks, followed by 20μg, im, twice per week after 2 weeks
Study: NCT01386242
Drug: Recombinant anti-tumor and anti-virus protein for injection
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant anti-tumor and anti-virus protein for injection, 10μg/1mL,im,three times per week for first 2 weeks, followed by 20μg,im, three times per week after 2 weeks.
Study: NCT01386242
Drug: Recombinant anti-tumor and anti-virus protein for injection
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant anti-tumor and anti-virus protein for injection, 10μg, im, three times per week for first week, followed by 20μg for two weeks, and followed by 30μg for a week, and followed a maintenance dose of 40μg, the frequency of administration is three times per week.
Study: NCT03217084
Drug: MI varnish GC
Approvals — FDA: no, EMA: no, PMDA: no
Description: MI Varnish GC is a 5% sodium fluoride varnish that has a desensitizing action when applied to tooth surfaces. MI Varnish also contains RECALDENT. Open the unit-dose package of Varnish. Use the applicator brush to thoroughly mix Varnish. Apply Varnish evenly in a thin layer over treatment area(s). For larger surface areas, apply Varnish in sweeping horizontal brush. After application, instruct the patient to close his or her mouth to set the Varnish. No need to use suction. The patient may feel the thin coating when rubbing the treated area with his or her tongue. The treatment period for Varnish is minimally 4 hour.
Study: NCT03217084
Drug: White varnish 3M
Normalized name: WHITE CURRANT
Approvals — FDA: no, EMA: no, PMDA: no
Description: White varnish 3M is a 5% sodium fluoride varnish that has a desensitizing action when applied to tooth surfaces. Clinpro White Varnish contains an innovative tri-calcium phosphate.Open the unit-dose package of Varnish and dispense the entire content onto the round application guide provided with the packet. Use the applicator brush to thoroughly mix Varnish. Apply Varnish evenly in a thin layer over treatment area(s). For larger surface areas, apply Varnish in sweeping horizontal brush. After application, instruct the patient to close his or her mouth to set the Varnish. No need to use suction. The patient may feel the thin coating when rubbing the treated area with his or her tongue. The treatment period for Varnish is minimally 4 hour.
Study: NCT01741831
Drug: No intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an observational study. Darunavir will be administered as per the recommended doses and will be given orally for a period of 24 weeks. For treatment naive (never received treatment for AIDS) patients: Darunavir 800 mg will be adminstered along with ritonavir 100 mg once daily. For experienced patients: Darunavir 600 mg will be administered along with ritonavir 100 mg twice daily.
Study: NCT04006210
Drug: Oral IR-LD/CD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encapsulated LD/CD 100mg/25mg
Study: NCT04006210
Drug: Placebo for Oral IR-LD/CD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encapsulated Placebo for LD/CD 100mg/25mg
Study: NCT00338273
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, 0 mg, Once daily, 8 weeks.
Study: NCT00554619
Drug: GSK1325760A
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5mg, 5mg or 10mg/day, po, GSK1325760A treatment will be continued until its approval by the MHLW.
Study: NCT00571636
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The experimental drug will be diluted according to each NICU scheme and administered as an attach dose of 1 mcg/kg in 30' followed by continuous i.v. infusion of 1 mcg/kg/h. Infusion of the experimental drug has to begin within 24 hrs from the beginning of MV and has to be continued until the end of MV and not after 7 days of life. If the newborn is still on MV after the 7th day of life he/she will be treated for pain according to local protocols.~Open label boluses of Fentanyl during the study phase will be administered, in both groups when the EDIN pain score is \> 6 and before performing the following invasive procedures:Peripherally inserted central venous catheter positioning;Re-intubation;Lumbar puncture;Pneumothorax or hydrothorax drainage.
Study: NCT00571636
Drug: 5% glucose solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: ev continuous infusion
Study: NCT00343369
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00343369
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00343369
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00343369
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00343369
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04589351
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT01800942
Drug: Azithromycin and Placebo
Normalized name: cefixime and azithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of 2g of Azithromycin will be given to the women in labour
Study: NCT03242772
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo tablets will be administered in the morning and provided for 11 weeks . The tablets will be titrated in the same way as the active drug and may be stopped at any time.
Study: NCT01638208
Drug: VSL#3
Normalized name: VSL#3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage Form: Capsules (Details as given below); Dose and duration of treatment: 1 capsule b.i.d for 8 weeks; Each capsule contains 112.5 Billion CFU of the following 8 strains of bacteria, 4 lactobacilli strains (L. acidophilus, L. plantarum, L. paracasei, L. delbrueckii subsp bulgaricus), 3 bifidobacteria strains (B. breve, B. infantis, B. longum) and 1 strain of S. thermophilus).
Study: NCT02393846
Drug: Ketoprofen gel
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ketoprofen as used in gel form.
Study: NCT02393846
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel which is identical in colour, form and smell compared to ketoprofen gel.
Study: NCT01015586
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 12 weeks
Study: NCT02759666
Drug: SHR3162
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR3162 capsule(s) is administered orally QD.
Study: NCT02788201
Drug: 75 approved agents
Normalized name: MISCELLANEOUS AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: One or combination of agents: Abiraterone, Arsenic Trioxide, Asparaginase Escherichia coli source, Axitinib, Azacitidine, Bendamustine, Bleomycin, Bortezomib, Busulfan, Carboplatin, Carfilzomib, Carmustine, Chlorambucil, Cisplatin, Cladribine, Clofarabine, Crizotinib, Cytarabine, Dacarbazine, Dactinomycin, Dasatinib, Daunorubicin, Decitabine, Docetaxel, Doxorubicin, Epirubicin, Eribulin, Erlotinib, Estramustine, Etoposide, Exemestane, Floxuridine, Fludarabine, Fluorouracil, Gefitinib, Gemcitabine, Hydroxyurea, Idarubicin, Ifosfamide, Imatinib, Irinotecan, Ixabepilone, Lapatinib, Lomustine, Mechlor, Melphalan, Mercapto, Methotrexate, Mitomycin, Mitotane, Mitoxantrone, Nilotinib, Oxaliplatin, Paclitaxel, Pazopanib, Pentostatin, Romidepsin, Ruxolitinib, Sorafenib, Streptozocin, Sunitinib, Tamoxifen, Temsirolimus, Teniposide, Thioguanine, Thiotepa, Topotecan, Toremifene, Tretinoin, Vandetanib, Vemurafenib, Vinblastine, Vincristine, Vismodegib, and/or Vorinostat
Study: NCT00977938
Drug: Placebo & Aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01561755
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - 2gr/kg over 2 days of saline
Study: NCT00622089
Drug: DIO-902
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150mg DIO-902 + 10mg atorvastatin
Study: NCT00622089
Drug: DIO-902
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg dose once per day for 24 weeks
Study: NCT00622089
Drug: DIO-902
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450mg dose once per day for 24 weeks
Study: NCT01632228
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matched with onartuzumab until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
Study: NCT02230761
Drug: XOPH5 Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02230761
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00353431
Drug: Novorapid ®, Novo Nordisk, Denmark
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of a sliding scale with an intensive s.c. scale
Study: NCT00113646
Drug: MEDI-507
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI-507 0.1 mg/kg on transplant day-8, 0.6 mg/kg on days-7 and -6
Study: NCT02363374
Drug: Induction Chemotherapy arm A
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive three induction chemotherapy cycles, starting on day 1, 15 and 29, consisting of:~Folinic acid: 400 mg/sqm, 2h-iv; Oxaliplatin: 100 mg/sqm, 2h-iv; 5-FU: 2400 mg/sqm, 46h-iv~After a break of two weeks, radiotherapy starts combined with:~5-FU: 250 mg/sqm per day, iv, on day 43-57, day 64-77 Oxaliplatin: 50 mg/sqm, day 43, 50, 64, and 71
Study: NCT02363374
Drug: Chemotherapy arm B
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemoradiotherapy is started according to the following schedule: 5-FU: 250 mg/sqm per day, iv, on day 1-14, day 22-35; Oxaliplatin: 50 mg/sqm, day 1, 8, 22, and 29.~After a break of two and a half weeks, patients receive three chemotherapy cycles, starting on day 57, 71 and 85, consisting of:~Folinic acid: 400 mg/sqm, 2h-iv; Oxaliplatin: 100 mg/sqm, 2h-iv; 5-FU: 2400 mg/sqm, 46h-iv
Study: NCT00033540
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 650 mg/m\^2 twice daily (BID), by mouth (PO) at 12 hour intervals, Days 1-14, every 21 days
Study: NCT00263640
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was given the same way as a subcutaneous (just under the skin) injection. Patients were treated according the same dosing schedule of active group. Children received lifestyle counselling.
Study: NCT02031081
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 X 100mg tablets (encapsulated) by mouth once daily for 28 days
Study: NCT03880448
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cornstarch 500mg/8h/7days
Study: NCT02086942
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction therapy：300mg/m2 VD Days 1-3 of each 28 day cycles,4 cycles. Intensive therapy：300mg/m2 VD Days 1-3 of each 28 day cycles,5 cycles. Maintenance treatment with CP: 200mg PO Days 1-14 of each 28 day cycles,12 cycles.
Study: NCT02466074
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo arm
Study: NCT01028716
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00619346
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets, BID X 14 days
Study: NCT01482897
Drug: Prednisolone acetate
Normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with corticoid (125mg in.5 ml)
Study: NCT01482897
Drug: sham procedure
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: feigning of peridural infiltration : anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with placement of empty syringe in peridural.
Study: NCT01482897
Drug: comparator : physiological solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with physiological solution (20 ml)
Study: NCT04214652
Drug: IDP-126 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDP-126 Gel applied topically to the face once daily for 12 weeks.
Study: NCT04214652
Drug: IDP-126 Vehicle Gel
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDP-126 Vehicle Gel applied topically to the face once daily for 12 weeks.
Study: NCT03778320
Drug: D-Serine
Normalized name: D-Serine
DrugBank: D-Serine (DB03929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose
Study: NCT03958591
Drug: CSII and thereafter combination therapy, followed up with wearable devices
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-term continuous subcutaneous insulin infusion and thereafter the combination therapy of basal insulin, metformin and vildagliptin; Wearable devices and smart apps will be used to manage and follow-up the participants.
Study: NCT03958591
Drug: CSII and thereafter combination therapy, followed up in traditional ways
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-term continuous subcutaneous insulin infusion and thereafter the combination therapy of basal insulin, metformin and vildagliptin; Traditional ways such as telephone contact will be used for follow up.
Study: NCT03958591
Drug: Traditionally upgrading therapy, followed up in traditional ways
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will be applied the combination therapy of basal insulin, metformin and vildagliptin for the entire 12 weeks. Traditional ways will be used for follow up.
Study: NCT00197145
Drug: GW873140
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg twice daily
Study: NCT04326036
Drug: Liberase Enzyme (Roche)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile Collagenase Blend to separate cSVF from the AD-SVF
Study: NCT00743028
Drug: ABT-263
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2 studies vs. a single dose of one of the new ABT-263 formulation
Study: NCT00743028
Drug: ABT-263
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2a studies vs. a single dose of a new ABT-263 formulation followed by QD dosing with a new ABT-263 formulation for 7 days.
Study: NCT01760473
Drug: Intranasal challenge drug
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each of the experimental challenge drugs were administered intranasally to all participants in random order.
Study: NCT00678535
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000 mg/m\^2 will be administered orally twice daily from evening of Day 1 to morning of Day 15 for every 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.
Study: NCT01537081
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets in two formulations to match either Mucinex or IR guaifenesin taken by mouth with a full glass of water
Study: NCT03452033
Drug: H-1337 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: H-1337 Placebo Vehicle
Study: NCT03452033
Drug: H-1337 [1]
Approvals — FDA: no, EMA: no, PMDA: no
Description: H-1337 Ophthalmic Solution Concentration 1
Study: NCT03452033
Drug: H-1337 [2]
Approvals — FDA: no, EMA: no, PMDA: no
Description: H-1337 Ophthalmic Solution Concentration 2
Study: NCT03452033
Drug: H-1337 [3]
Approvals — FDA: no, EMA: no, PMDA: no
Description: H-1337 Ophthalmic Solution Concentration 3
Study: NCT01192503
Drug: placebo (sugar pill)
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1mg (2 tablets of 0.5mg) taken at bedtime by mouth for 12 weeks
Study: NCT02937857
Drug: Standard treatment only
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard treatment， such as antiasthmatic,expectorant,antipyretic
Study: NCT02937857
Drug: Standard treatment+Xiyanping injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard treatment+Xiyanping injection:standard treatment， such as antiasthmatic, expectorant and antipyretic plus Xiyanping injection,0.2-0.4mL/kg/day,qd for 5 days.
Study: NCT00652184
Drug: ARYS-01 (sorivudine) cream 3% or placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorivudine cream 3% or placebo cream twice daily for 10 days
Study: NCT00652184
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo cream and placebo valaciclovir
Study: NCT03666351
Drug: Amlodipine/Losartan/Chlorthalidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 5 mg/Losartan Potassium 100 mg/Chlorthalidone 12.5 mg
Study: NCT03666351
Drug: current treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment is done by maintaining the current treatment
Study: NCT03670355
Drug: Placebo IVR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contains placebo
Study: NCT03404908
Drug: Ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ketoprofen will be used (0.1 gram), up to 200 milligrams per day
Study: NCT00612742
Drug: testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: once daily transdermal testosterone gel, 300 mcg
Study: NCT00612742
Drug: placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily transdermal placebo gel
Study: NCT03283098
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo supplied to match active intervention.
Study: NCT03980821
Drug: AZD4635
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD4635 taken orally